The Israel-based biopharma company said a Phase IIb trial of its oral treatment of non-alcoholic steatohepatitis hit the necessary endpoints to support a Phase III trial and FDA marketing application.
Galmed Pharmaceuticals Ltd. said it will soon enter talks with the US FDA on designing a Phase III trial of its liver-targeted SCD1 modulator Aramchol for treating non-alcoholic steatohepatitis (NASH) after positive Phase IIb top-line data showed it met the necessary endpoints.
The NASDAQ-listed Israeli company said the Phase IIb ARREST study of its lead drug candidate supported a pivotal trial and...
Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.
The Belgian drugmaker is boosting its biologics capacity over the pond.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
